Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Kraenzlin

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Therapeutische Umschau. Revue Therapeutique|December 29, 1998
[Diagnostic procedure in the woman]M E Kraenzlin
Revue Medicale Suisse|July 5, 2013
[Swiss guidance for the diagnosis and management of osteoporosis]M E Kraenzlin
MMW Fortschritte Der Medizin|July 24, 2002
[Diagnosis of osteoporosis. How do you manage it?]M E Kraenzlin
Annales D'Endocrinologie|April 28, 2006
Practical use of biochemical markers of bone turnoverM E Kraenzlin
Revue Medicale Suisse|July 25, 2009
[Thiazolidinediones and skeletal health]C Meier, M Bodmer, C R Meier, et al.
Gut|May 1, 1985
Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responsesS M Wood, M E Kraenzlin, T E Adrian, et al.
Schweizerische Medizinische Wochenschrift|April 19, 1997
[Epidemiology of osteoporosis]J P Bonjour, P Burckhardt, M Dambacher, et al.
Lancet (London, England)|December 24, 1983
Can inhibition of hormone secretion be associated with endocrine tumour shrinkage?M E Kraenzlin, J C Ch'ng, S M Wood, et al.
JAMA|June 24, 2000
HMG-CoA reductase inhibitors and the risk of fracturesC R Meier, R G Schlienger, M E Kraenzlin, et al.
JAMA|August 10, 2001
Statins and fracture riskC R Meier, R G Schlienger, M E Kraenzlin, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Therapeutische Umschau. Revue Therapeutique|December 29, 1998
[Diagnostic procedure in the woman]M E Kraenzlin
Revue Medicale Suisse|July 5, 2013
[Swiss guidance for the diagnosis and management of osteoporosis]M E Kraenzlin
MMW Fortschritte Der Medizin|July 24, 2002
[Diagnosis of osteoporosis. How do you manage it?]M E Kraenzlin
Annales D'Endocrinologie|April 28, 2006
Practical use of biochemical markers of bone turnoverM E Kraenzlin
Revue Medicale Suisse|July 25, 2009
[Thiazolidinediones and skeletal health]C Meier, M Bodmer, C R Meier, et al.
Gut|May 1, 1985
Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responsesS M Wood, M E Kraenzlin, T E Adrian, et al.
Schweizerische Medizinische Wochenschrift|April 19, 1997
[Epidemiology of osteoporosis]J P Bonjour, P Burckhardt, M Dambacher, et al.
Lancet (London, England)|December 24, 1983
Can inhibition of hormone secretion be associated with endocrine tumour shrinkage?M E Kraenzlin, J C Ch'ng, S M Wood, et al.
JAMA|June 24, 2000
HMG-CoA reductase inhibitors and the risk of fracturesC R Meier, R G Schlienger, M E Kraenzlin, et al.
JAMA|August 10, 2001
Statins and fracture riskC R Meier, R G Schlienger, M E Kraenzlin, et al.
Pageof 3